Skip to main content
. 2019 May 1;10:387. doi: 10.3389/fphar.2019.00387

Figure 3.

Figure 3

The forest plot of pooled ORR (A), 6-month PFS rate (C), 6-month OS rate (D) in patients received nivolumab or pembrolizumab; the forest plot of pooled ORR in patients with HL or NHL (B).